Literature DB >> 21412203

Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans.

Utkarsh Kohli1, Maureen K Hahn, Brett A English, Gbenga G Sofowora, Mordechai Muszkat, Chun Li, Randy D Blakely, C Michael Stein, Daniel Kurnik.   

Abstract

BACKGROUND: The presynaptic norepinephrine transporter (NET) mediates synaptic clearance and recycling of norepinephrine. NET-deficient transgenic mice have elevated blood pressure (BP), heart rate, and catecholamine concentrations. However, the in-vivo effects of common NET variants on cardiovascular regulation at rest and during exercise are unknown.
METHODS: We studied cardiovascular responses and plasma catecholamine concentrations at rest and during bicycle exercise at increasing workloads (25, 50, and 75 W) in 145 healthy participants. We used multiple linear regressions to analyze the effect of common, purportedly functional polymorphisms in NET (rs2242446 and rs28386840) on cardiovascular measures.
RESULTS: 44 and 58.9% of participants carried at least one variant allele for NET T-182C and A-3081T, respectively. Systolic BP during exercise and systolic BP-area under the curve were higher in carriers of variant NET alleles (P=0.003 and 0.009 for T-182C and A-3081T, respectively) and NET haplotype -182C/-3081T compared with -182T/-3081A (all P<0.01). Diastolic BP during exercise was also higher at lower, but not at higher exercise stages in carriers of NET -182C (P<0.01) and -3081T variants (P<0.05). NET genotypes were not associated with catecholamine concentrations or heart rate.
CONCLUSION: Common genetic NET variants (-182C and -3081T) are associated with greater BP response to exercise in humans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412203      PMCID: PMC3065933          DOI: 10.1097/FPC.0b013e328344f63e

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  37 in total

Review 1.  Individual differences in response to regular physical activity.

Authors:  C Bouchard; T Rankinen
Journal:  Med Sci Sports Exerc       Date:  2001-06       Impact factor: 5.411

2.  Compendium of physical activities: an update of activity codes and MET intensities.

Authors:  B E Ainsworth; W L Haskell; M C Whitt; M L Irwin; A M Swartz; S J Strath; W L O'Brien; D R Bassett; K H Schmitz; P O Emplaincourt; D R Jacobs; A S Leon
Journal:  Med Sci Sports Exerc       Date:  2000-09       Impact factor: 5.411

3.  Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance.

Authors:  Christoph Schroeder; Jens Tank; Michael Boschmann; Andre Diedrich; Arya M Sharma; Italo Biaggioni; Friedrich C Luft; Jens Jordan
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

4.  Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency.

Authors:  J R Shannon; N L Flattem; J Jordan; G Jacob; B K Black; I Biaggioni; R D Blakely; D Robertson
Journal:  N Engl J Med       Date:  2000-02-24       Impact factor: 91.245

5.  A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade.

Authors:  G G Sofowora; V Dishy; M Muszkat; H G Xie; R B Kim; P A Harris; H C Prasad; D W Byrne; U B Nair; A J J Wood; C M Stein
Journal:  Clin Pharmacol Ther       Date:  2003-04       Impact factor: 6.875

6.  Pharmacological properties of naturally occurring variants of the human norepinephrine transporter.

Authors:  F Runkel; M Brüss; M M Nöthen; G Stöber; P Propping; H Bönisch
Journal:  Pharmacogenetics       Date:  2000-07

7.  Variability within alpha- and beta-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge.

Authors:  Jeanne M McCaffery; Michael F Pogue-Geile; Robert E Ferrell; Nancy Petro; Stephen B Manuck
Journal:  J Hypertens       Date:  2002-06       Impact factor: 4.844

8.  Genome-wide linkage analysis of systolic and diastolic blood pressure: the Québec Family Study.

Authors:  T Rice; T Rankinen; M A Province; Y C Chagnon; L Pérusse; I B Borecki; C Bouchard; D C Rao
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

9.  Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception.

Authors:  Utkarsh Kohli; Mordechai Muszkat; Gbenga G Sofowora; Paul A Harris; Eitan A Friedman; William D Dupont; Mika Scheinin; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Eur J Pain       Date:  2009-05-06       Impact factor: 3.931

10.  A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters.

Authors:  Maureen K Hahn; David Robertson; Randy D Blakely
Journal:  J Neurosci       Date:  2003-06-01       Impact factor: 6.167

View more
  10 in total

Review 1.  Vesicular and plasma membrane transporters for neurotransmitters.

Authors:  Randy D Blakely; Robert H Edwards
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

2.  Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise.

Authors:  Utkarsh Kohli; André Diedrich; Prince J Kannankeril; Mordechai Muszkat; Gbenga G Sofowora; Maureen K Hahn; Brett A English; Randy D Blakely; C Michael Stein; Daniel Kurnik
Journal:  Physiol Genomics       Date:  2015-06-09       Impact factor: 3.107

3.  Differentiation of rodent behavioral phenotypes and methylphenidate action in sustained and flexible attention tasks.

Authors:  Richard Chu; Jed Shumsky; Barry D Waterhouse
Journal:  Brain Res       Date:  2015-12-10       Impact factor: 3.252

4.  Catecholamine pathway gene variation is associated with norepinephrine and epinephrine concentrations at rest and after exercise.

Authors:  Laxmi V Ghimire; Utkarsh Kohli; Chun Li; Gbenga G Sofowora; Mordechai Muszkat; Eitan A Friedman; Joseph F Solus; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

5.  Norepinephrine transporter heterozygous knockout mice exhibit altered transport and behavior.

Authors:  H M Fentress; R Klar; J J Krueger; T Sabb; S N Redmon; N M Wallace; J K Shirey-Rice; M K Hahn
Journal:  Genes Brain Behav       Date:  2013-10-09       Impact factor: 3.449

Review 6.  SLC6 transporters: structure, function, regulation, disease association and therapeutics.

Authors:  Akula Bala Pramod; James Foster; Lucia Carvelli; L Keith Henry
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

7.  Effect of the rs168924 single-nucleotide polymorphism in the SLC6A2 catecholamine transporter gene on blood pressure in Caucasians.

Authors:  Oliver Zolk; Christian Ott; Martin F Fromm; Roland E Schmieder
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-04-09       Impact factor: 3.738

8.  Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial.

Authors:  Thomas Liebe; Shijia Li; Anton Lord; Lejla Colic; Anna Linda Krause; Anil Batra; Moritz A Kretzschmar; Catherine M Sweeney-Reed; Gusalija Behnisch; Björn H Schott; Martin Walter
Journal:  Int J Neuropsychopharmacol       Date:  2017-11-01       Impact factor: 5.176

9.  Ketamine influences the locus coeruleus norepinephrine network, with a dependency on norepinephrine transporter genotype - a placebo controlled fMRI study.

Authors:  Thomas Liebe; Meng Li; Lejla Colic; Matthias H J Munk; Catherine M Sweeney-Reed; Marie Woelfer; Moritz A Kretzschmar; Johann Steiner; Felicia von Düring; Gusalija Behnisch; Björn H Schott; Martin Walter
Journal:  Neuroimage Clin       Date:  2018-09-04       Impact factor: 4.881

10.  No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA.

Authors:  Patrick Vizeli; Henriette E Meyer Zu Schwabedissen; Matthias E Liechti
Journal:  Eur J Clin Pharmacol       Date:  2017-12-02       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.